¼¼°èÀÇ ½ÅÀå ½Å°æ Á¦°Å ±â¼ú ½ÃÀå
Renal Denervation Technologies
»óǰÄÚµå : 1765170
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 107 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,171,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,515,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÅÀå ½Å°æ Á¦°Å ±â¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 31¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 3¾ï 7,830¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÅÀå ½Å°æ Á¦°Å ±â¼ú ¼¼°è ½ÃÀåÀº2024-2030³â ºÐ¼® ±â°£¿¡ CAGR 41.7%¼ºÀåÀ» ÀÌ·ç¾î 2030³â¿¡´Â 31¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °íÁÖÆÄ ±â¹ÝÀº CAGR 41.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 21¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÃÊÀ½ÆÄ ±â¹Ý ºÎ¹®Àº ºÐ¼® ±â°£ CAGRÀÌ 43.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9,040¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR51.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÅÀå ½Å°æ Á¦°Å ±â¼ú ½ÃÀåÀº 2024³â¿¡ 9,040¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2¾ï 4,990¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 51.7%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, °¢°¢ ºÐ¼® ±â°£ Áß¿¡ 34.4%¿Í 38.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 38.4%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ½ÅÀå ½Å°æ Á¦°Å ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½ÅÀå ½Å°æ Á¦°Å ±â¼úÀº ¿©·¯ °¡Áö Ç×°íÇ÷¾ÐÁ¦¸¦ »ç¿ëÇßÀ½¿¡µµ ºÒ±¸ÇÏ°í °íÇ÷¾ÐÀÌ Á¶ÀýµÇÁö ¾Ê´Â ÀúÇ×¼º °íÇ÷¾Ð Ä¡·á¿¡ ÀÖ¾î À¯¸ÁÇÑ ¹ßÀüÀÔ´Ï´Ù. ÀÌ ÃÖ¼Òħ½ÀÀû ¼ö¼úÀº Ä«Å×Å͸¦ ÀÌ¿ëÇÑ °íÁÖÆÄ ¶Ç´Â ÃÊÀ½ÆÄ ¿¡³ÊÁö¸¦ ÀÌ¿ëÇÏ¿© ½ÅÀåÀ¸·Î ¿¬°áµÇ´Â µ¿¸Æ ÁÖº¯¿¡ ÀÖ´Â ½ÅÀå ½Å°æÀ» ÀýÁ¦ÇÏ´Â ¼ö¼úÀÔ´Ï´Ù. ½ÅÀå ½Å°æ Á¦°Å ±â¼úÀº ÀÌ ½Å°æÀ» ÅëÇØ Àü´ÞµÇ´Â ½ÅÈ£¸¦ Â÷´ÜÇÏ¿© ±³°¨½Å°æ°èÀÇ È°µ¿À» ¾ïÁ¦Çϰí Ç÷¾ÐÀ» ³·Ãß´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. ÀÌ ½Ã¼úÀº ÀϹÝÀûÀ¸·Î ±¹¼Ò ¸¶ÃëÇÏ¿¡ ´ëÅ𵿸ÆÀ» ÅëÇØ Ä«Å×Å͸¦ »ðÀÔÇÏ¿© ½ÅÀå µ¿¸ÆÀ¸·Î À¯µµÇÏ¿© Ç¥Àû ÀýÁ¦¼úÀ» ½ÃÇàÇÕ´Ï´Ù. ÀÌ ½Ã¼úÀº Ç÷¾ÐÀ» ³·Ãß´Â °Í»Ó¸¸ ¾Æ´Ï¶ó Áö¼ÓÀûÀÎ È¿°ú¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ´Â °¡´É¼ºÀ» º¸¿© ±âÁ¸ÀÇ Ä¡·á¹ýÀ¸·Î ÃæºÐÇÑ È¿°ú¸¦ ¾òÁö ¸øÇÑ È¯Àڵ鿡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀ¸·Î ½ÅÀå ½Å°æÀýÁ¦¼úÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. Ãʱâ ÀÓ»ó½ÃÇèÀº ÀϰüµÈ °á°ú¸¦ ¾òÁö ¸øÇÏ´Â ¹®Á¦¿¡ Á÷¸éÇÏ¿© ±â¼úÀÇ Çõ½Å°ú °³¼±À» ÃËÁøÇß½À´Ï´Ù. ÃֽŠ½Ã½ºÅÛÀº Ä«Å×ÅÍ ¼³°è°¡ °³¼±µÇ¾î ´õ ³ªÀº Ž»ö ¹× ¿¡³ÊÁö Á¶»ç Á¤È®µµ¸¦ Á¦°øÇÏ¿© ÁÖº¯ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çß½À´Ï´Ù. ¶ÇÇÑ, ¿µ»ó Áø´Ü ¹× ¸ÅÇÎ ±â¼úÀÇ ¹ßÀüÀ¸·Î ½ÅÀå ½Å°æÀ» º¸´Ù Á¤È®ÇÏ°Ô Á¶ÁØÇÒ ¼ö ÀÖ°Ô µÇ¾î È¿°úÀûÀÎ ÀýÁ¦¼úÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ÃÊÀ½ÆÄ³ª È­ÇÐÀû ÀýÁ¦¼ú°ú °°Àº °íÁ֯ď¦ »ç¿ëÇÏÁö ¾Ê´Â ¹æ¹ý¿¡ ´ëÇÑ °ü½Éµµ Áõ°¡Çϰí ÀÖÀ¸¸ç, °íÀ¯ÇÑ ÀåÁ¡À» °¡Áø ´ëü Á¢±Ù¹ýÀÌ Á¦°øµÇ°í ÀÖ½À´Ï´Ù. ²÷ÀÓ¾ø´Â ¿¬±¸ °³¹ßÀ» ÅëÇØ °íÇ÷¾ÐÀÇ ±âÀú¿¡ ÀÖ´Â »ý¸®Àû ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁö¸é¼­ º¸´Ù È¿°úÀûÀÌ°í °³Àο¡ ¸Â´Â ½ÅÀå ½Å°æÀýÁ¦¼ú Àü·«ÀÌ È®¸³µÇ°í ÀÖ½À´Ï´Ù.

½ÅÀå ½Å°æÀýÁ¦¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °íÇ÷¾Ð, ƯÈ÷ ÀúÇ×¼º °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡´Â Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼úÀÇ ¹ßÀü°ú °íÇ÷¾ÐÀÇ º´Å»ý¸®¿¡ ´ëÇÑ ±íÀº ÀÌÇØ´Â º¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ½ÅÀå Á¦¼¼µ¿ ½Ã½ºÅÛÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­, ½Ä½À°üÀÇ º¯È­, ÁÂ½Ä »ýȰ°ú °°Àº »ýȰ½À°ü ¿äÀΰú ÇÔ²² °íÇ÷¾Ð ¹ßº´·ü Áõ°¡´Â ÀÌ·¯ÇÑ ±â¼úÀÇ ÀáÀçÀû ½ÃÀåÀ» ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÀå ½Å°æÂ÷´Ü¼úÀÇ Àå±âÀûÀÎ ÇýÅðú ¾ÈÀü¼ºÀ» µÞ¹ÞħÇÏ´Â ÀÓ»óÀû ±Ù°Å°¡ ÃàÀûµÊ¿¡ µû¶ó ´õ ¸¹Àº ÀÇ·áÁøÀÌ ÀÌ Ä¡·á¹ýÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ȸº¹ ±â°£ÀÌ Âª°í ÇÕº´ÁõÀÌ ÀûÀº Ä¡·á¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¼±È£¿Í Çö´ë ÀÇÇп¡¼­ ÃÖ¼Ò Ä§½ÀÀû Ä¡·á¸¦ ¼±È£ÇÏ´Â Ãß¼¼µµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ½ÅÀå ½Å°æÂ÷´Ü¼ú ½ÃÀåÀÌ ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ¹ßÀüÇϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

ºÎ¹®

±â¼ú(°íÁÖÆÄ ±â¹Ý, ÃÊÀ½ÆÄ ±â¹Ý, ¸¶ÀÌÅ©·ÎÀÎÇ»Àü ±â¹Ý)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

°ËÁõ µÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Renal Denervation Technologies Market to Reach US$3.1 Billion by 2030

The global market for Renal Denervation Technologies estimated at US$378.3 Million in the year 2024, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 41.7% over the analysis period 2024-2030. Radiofrequency Based, one of the segments analyzed in the report, is expected to record a 41.3% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Ultrasound Based segment is estimated at 43.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$90.4 Million While China is Forecast to Grow at 51.7% CAGR

The Renal Denervation Technologies market in the U.S. is estimated at US$90.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$249.9 Million by the year 2030 trailing a CAGR of 51.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 34.4% and 38.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 38.4% CAGR.

Global Renal Denervation Technologies Market - Key Trends & Drivers Summarized

Renal denervation technologies represent a promising advancement in the treatment of resistant hypertension, a condition where high blood pressure remains uncontrolled despite the use of multiple antihypertensive medications. This minimally invasive procedure involves the use of catheter-based radiofrequency or ultrasound energy to ablate the renal nerves, which are located around the arteries leading to the kidneys. By disrupting the signals transmitted through these nerves, renal denervation aims to reduce sympathetic nervous system activity, thereby lowering blood pressure. The procedure is typically performed under local anesthesia and involves the insertion of a catheter through the femoral artery, guided to the renal arteries, where targeted ablation is conducted. The technique has shown potential not only in reducing blood pressure but also in offering sustained effects, making it an attractive option for patients who do not respond adequately to conventional therapies.

Technological advancements have significantly enhanced the efficacy and safety of renal denervation procedures. Early clinical trials faced challenges with inconsistent results, prompting further innovation and refinement in the technology. Modern systems now offer improved catheter designs with better navigability and precision in delivering energy, which minimizes damage to surrounding tissues and enhances patient outcomes. Additionally, advancements in imaging and mapping technologies allow for more accurate targeting of the renal nerves, ensuring effective ablation. There has also been a growing interest in non-radiofrequency methods, such as ultrasound and chemical ablation, which provide alternative approaches with their own unique benefits. Continuous research and development are expanding the understanding of the physiological mechanisms underlying hypertension, leading to more effective and tailored renal denervation strategies.

The growth in the renal denervation technologies market is driven by several factors. The increasing prevalence of hypertension worldwide, particularly resistant hypertension, is a major driver, as it fuels the demand for innovative treatment options. Advances in medical technology and a deeper understanding of the pathophysiology of hypertension have led to the development of more effective and safer renal denervation systems. The aging global population, coupled with lifestyle factors such as poor diet and sedentary behavior, contributes to the rising incidence of hypertension, further expanding the potential market for these technologies. Additionally, the growing body of clinical evidence supporting the long-term benefits and safety of renal denervation is encouraging more healthcare providers to adopt this treatment modality. The push for minimally invasive procedures in modern medicine, driven by patient preference for treatments with shorter recovery times and fewer complications, also supports market growth. These factors collectively highlight the dynamic and rapidly evolving nature of the renal denervation technologies market.

SCOPE OF STUDY:

The report analyzes the Renal Denervation Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Radiofrequency Based, Ultrasound Based, Micro-Infusion Based)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 13 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â